Free tool
FAERS Monitor: Sprycel
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021986 or its brand name (Sprycel, Dasatinib). Reports on generic versions are filed under their own applications.
Reports
37,260
Serious
22,458
60% of reports
Hospitalization
8,860
Death reported
3,748
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pleural effusion3,282
- fatigue2,554
- diarrhoea2,178
- nausea2,151
- death2,131
- headache2,014
- rash1,618
- drug ineffective1,554
- dyspnoea1,513
- adverse event1,478
- off label use1,321
- hospitalisation1,223
- pulmonary oedema1,016
- vomiting961
- pyrexia898
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 94 |
| 2007 | 313 |
| 2008 | 417 |
| 2009 | 406 |
| 2010 | 519 |
| 2011 | 522 |
| 2012 | 1,181 |
| 2013 | 1,281 |
| 2014 | 2,403 |
| 2015 | 2,571 |
| 2016 | 2,506 |
| 2017 | 2,408 |
| 2018 | 2,703 |
| 2019 | 3,279 |
| 2020 | 2,830 |
| 2021 | 2,942 |
| 2022 | 2,643 |
| 2023 | 2,739 |
| 2024 | 2,897 |
| 2025 | 1,632 |
| 2026 | 974 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,016,899 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pleural effusionSignal | 3,282 | 32.1 | 31.1 | 93,864 |
| pulmonary oedemaSignal | 1,016 | 13.1 | 12.3 | 11,094 |
| adverse eventSignal | 1,478 | 9.2 | 8.7 | 10,645 |
| hospitalisationSignal | 1,223 | 4.5 | 4.3 | 3,348 |
| rashSignal | 1,618 | 2.1 | 2.0 | 947 |
| diarrhoea | 2,178 | 1.9 | 1.8 | 966 |
| fatigue | 2,554 | 1.9 | 1.8 | 1,040 |
| headache | 2,014 | 1.8 | 1.7 | 758 |
| nausea | 2,151 | 1.5 | 1.5 | 416 |
| dyspnoea | 1,513 | 1.5 | 1.4 | 267 |
| pyrexia | 898 | 1.5 | 1.4 | 135 |
| death | 2,131 | 1.4 | 1.3 | 250 |
| vomiting | 961 | 1.2 | 1.1 | 20 |
| off label use | 1,321 | 0.9 | 0.8 | 36 |
| drug ineffective | 1,554 | 0.7 | 0.6 | 279 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.